Repligen Executive and Leadership Team

Olivier Loeillot, the Chief Executive Officer at Repligen, directs the overarching corporate strategy and long-term vision for the bioprocessing organization. By prioritizing innovation in biologic drug production, Loeillot guides the company toward sustainable growth within the competitive life sciences sector. This leadership role involves constant engagement with the Board to ensure alignment between market demands and internal product development cycles. Overseeing global expansion initiatives, the Chief Executive Officer maintains a focus on scaling manufacturing capabilities to meet the needs of international pharmaceutical partners. Olivier Loeillot drives the integration of new technologies into the existing product portfolio, ensuring that the company remains at the forefront of bioprocessing advancements. Through consistent evaluation of market trends, the Chief Executive Officer secures the competitive position of the firm, fostering a culture of excellence that supports the delivery of high-value solutions to clients across diverse geographic markets.

Jason Garland, the Chief Financial Officer at Repligen, manages the fiscal health and capital allocation strategies essential for supporting bioprocessing innovation. By overseeing financial planning, reporting, and investor relations, the Chief Financial Officer ensures the company maintains the resources required for continuous research and development. Jason Garland directs the financial modeling that informs major investment decisions, including potential acquisitions and infrastructure upgrades. This role requires close collaboration with other executive leaders to balance operational spending with the pursuit of long-term revenue growth. By optimizing the capital structure, the Chief Financial Officer provides the stability necessary for the firm to navigate the complexities of the global life sciences market. Garland monitors economic indicators and regulatory changes to mitigate financial risks, ensuring that the organization remains agile while delivering consistent value to shareholders through disciplined fiscal management and strategic resource deployment.

James Bylund, the Chief Operating Officer at Repligen, executes the daily operational strategies that drive the production of high-value bioprocessing components. By managing the supply chain and manufacturing workflows, the Chief Operating Officer ensures that the company meets the rigorous quality standards required for biologic drug production. James Bylund oversees the integration of lean manufacturing principles to enhance efficiency across all production facilities. This leadership role involves coordinating with cross-functional teams to streamline product delivery and improve operational throughput. By focusing on process optimization, the Chief Operating Officer supports the company mission of providing flexible solutions to pharmaceutical manufacturers. Bylund directs the implementation of scalable systems that allow the organization to respond rapidly to shifts in market demand. Through meticulous oversight of operational performance metrics, the Chief Operating Officer maintains the high standards of reliability that define the company presence in the global bioprocessing industry.

Keith Lee Lee Robinson, the Chief Information Officer at Repligen, architects the digital infrastructure and data security frameworks that support the company bioprocessing operations. By implementing advanced information systems, the Chief Information Officer enables seamless data flow between research, manufacturing, and administrative departments. Keith Lee Lee Robinson directs the cybersecurity initiatives that protect proprietary intellectual property and sensitive client information. This role involves evaluating emerging technologies to enhance internal productivity and improve the digital experience for global customers. By leveraging data analytics, the Chief Information Officer provides actionable insights that inform strategic decision-making across the executive team. Robinson ensures that the technological foundation remains robust and scalable, allowing the organization to adapt to the evolving digital requirements of the life sciences sector. Through the management of enterprise software and network integrity, the Chief Information Officer maintains the connectivity and security necessary for the company to sustain its leadership in bioprocessing innovation.